The rate of goal achievement was comparable to the level of improvement in symptom severity assessed by visual analogue scale but not comparable to symptom severity assessed by the voiding diary. Another single-arm

study was conducted to evaluate goal achievement after 12-week medication with oxybutynin in men and women with OAB symptoms using a 6-point Likert scale (0 = not at all achieved; ∼5 Ibrutinib solubility dmso = completely achieved).11 Symptom relief was the most common goal in 72%, and daytime frequency was the most common target symptom. After treatment, 42% of patients successfully achieved their goals, and the median goal achievement score was 3 points (Table 1). Among baseline demographics and symptom severity, only age had a negative relationship with goal achievement score. Goal achievement had a weak correlation

with satisfaction and a moderate correlation with treatment benefit. More importantly, it was the measure that best correlated with both satisfaction and treatment benefit. Cartwright et al.12 conducted a randomized, placebo-controlled, double-blind trial to assess goal achievement after 4-week treatment with transdermal oxybutynin. A majority of the goals related to symptoms and goal achievement were low for both the transdermal oxybutynin (42%) and the placebo patch (32%) selleck screening library groups, without significant differences. They also observed no significant difference in the improvement in a disease-specific quality of life questionnaire (King’s Health Questionnaire) between oxybutynin and the placebo patch. The study might have more value in revealing a

high placebo effect in goal achievement than in reporting the efficacy of transdermal oxybutynin. The authors concluded that the disparity between the good results observed in the previous clinical trial13–16 and failure to achieve goals in their study could explain poor persistence and BCKDHB patient disillusionment, which are common in real practice of antimuscarinic treatment. Benign prostatic obstruction (BPO) is a common cause of LUTS in aging men and has a substantial impact on quality of life. Although LUTS are currently divided into storage, voiding, and postvoiding symptoms, patients with BPO frequently report a combination of symptoms. Thus, it is important to identify the most bothersome symptom in each patient and to know how much therapy improves the symptom. The most bothersome symptom and symptom-specific goal achievement after medical treatment with an alpha-blocker were evaluated in 108 men with BPO using a 6-point Likert scale.17 The scores were divided into four categories: successfully achieved, 4 or 5; half achieved, 3; less than half achieved, 1 or 2; and not achieved at all, 0.